TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25849049

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES)
Number of subjects: 50
Study: 23981319

Group type: EXPERIMENTAL
Intervention: Visceral osteopathy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo manipulations
Number of subjects: 31
Study: 21721148

Group type: EXPERIMENTAL
Intervention: Acupuncture at Waiguan points (TE5) on left hands for 20 minutes
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 24
Study: 19782419

Group type: COMPARATOR
Intervention: CEOP
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: CEOP plus semustine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Prognostic index (low risk, intermediate risk, high risk)
Number of subjects: 75
Study: 16877719

Group type: EXPERIMENTAL
Intervention: Arm 1: Bolus FU in two 5-day cycles every 28 days before and after radiotherapy plus FU via protracted venous infusion (PVI) 225 mg/m2/d during XRT
Number of subjects: 1917

Group type: EXPERIMENTAL
Intervention: Arm 2: PVI-only arm, with PVI 42 days before and 56 days after XRT + PVI
Number of subjects: 1917

Group type: EXPERIMENTAL
Intervention: Arm 3: Bolus-only arm, with bolus FU + leucovorin (LV) in two 5-day cycles before and after XRT, plus bolus FU + LV
Number of subjects: 1917
Study: 12741422

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Washed wound drainage transfusion
Number of subjects: 40
Study: 10971308

Group type: EXPERIMENTAL
Intervention: 150 mg PSC (valspodar) as an i.v. infusion over 2 h
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Morphine HCl (7.5 mg) infused over 2 h
Number of subjects: 18

Group type: COMPARATOR
Intervention: PSC alone
Number of subjects: 18
Study: 8839839

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HY)
Number of subjects: 105

Group type: COMPARATOR
Intervention: VP16
Number of subjects: 105
Study: 1477492

Group type: EXPERIMENTAL
Intervention: Intensive individual training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Less intensive group training
Number of subjects: 14
Study: 6384636

Group type: EXPERIMENTAL
Intervention: Pindolol 1% eyedrops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pindolol 0.17% eyedrops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pindolol 0.35% eyedrops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pindolol 0.5% eyedrops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pindolol 0.72% eyedrops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pindolol 1.0% eyedrops
Number of subjects: 0
Study: 29756496

Group type: EXPERIMENTAL
Intervention: 1-stage procedure
Number of subjects: 180

Group type: COMPARATOR
Intervention: 2-stage procedure
Number of subjects: 180
Study: 29909855

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) for 1 month, n=29
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (C), n=21
Number of subjects: 50
Study: 26950098

Group type: EXPERIMENTAL
Intervention: Guided self-instruction (booklet with self-instructions and e-mail contact with a therapist)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 100
Study: 24140172

Group type: EXPERIMENTAL
Intervention: 3-min isokinetic all-out test at 60 rpm
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 3-min isokinetic all-out test at 100 rpm
Number of subjects: 14

Group type: COMPARATOR
Intervention: Incremental ramp testing
Number of subjects: 14
Study: 22370314

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg daily)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Gemcitabine and Cisplatin (GP) chemotherapy (gemcitabine 1,250 mg/m2 on days 1 and 8; cisplatin 80 mg/m2 on day 1 every 3 weeks, for up to nine courses)
Number of subjects: 313
Study: 19559965

Group type: EXPERIMENTAL
Intervention: Children with CRS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Children without CRS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Children with severe CRS
Number of subjects: 40
Study: 17623745

Group type: EXPERIMENTAL
Intervention: Infliximab therapy
Number of subjects: 33
Study: 15896183

Group type: COMPARATOR
Intervention: Zinc supplementation
Number of subjects: 392

Group type: COMPARATOR
Intervention: Vitamin A supplementation
Number of subjects: 392

Group type: COMPARATOR
Intervention: Combined zinc and vitamin A supplementation
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 392
Study: 12100939

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 89

Group type: COMPARATOR
Intervention: Lanolin hand cream
Number of subjects: 89

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 89
Study: 11213007

Group type: EXPERIMENTAL
Intervention: Anti-smoking education in pregnancy
Number of subjects: 1823

Group type: EXPERIMENTAL
Intervention: Maternal smoking behaviour
Number of subjects: 1823

Group type: EXPERIMENTAL
Intervention: Alternative classifications of smoking behaviour
Number of subjects: 1823
Study: 9137929

Group type: EXPERIMENTAL
Intervention: Carbimazole + Propranolol (40 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Carbimazole + Placebo
Number of subjects: 7
Study: 7966415

Group type: EXPERIMENTAL
Intervention: Multivariate predictive models using tumor size, patient age, S phase, and PgR as independent predictors.
Number of subjects: 11964

Group type: EXPERIMENTAL
Intervention: Addition of prognostic indicator information to tumor size.
Number of subjects: 11964

Group type: EXPERIMENTAL
Intervention: Predictive models.
Number of subjects: 11964
Study: 3298419

Group type: EXPERIMENTAL
Intervention: 50% reduction of cis(z)‐flupenthixol decanoate
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pre-trial dosage of cis(z)‐flupenthixol decanoate
Number of subjects: 18
Study: 29890982

Group type: EXPERIMENTAL
Intervention: PPFP intervention package
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 27209291

Group type: EXPERIMENTAL
Intervention: Oral lusutrombopag (14-day once-daily dosing)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Oral lusutrombopag
Number of subjects: 78
Study: 25311610

Group type: EXPERIMENTAL
Intervention: 500 mg resveratrol capsule
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 50
Study: 23602776

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice-daily
Number of subjects: 15526

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg twice-daily
Number of subjects: 15526

Group type: EXPERIMENTAL
Intervention: Combined rivaroxaban group
Number of subjects: 15526

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15526
Study: 20950174

Group type: EXPERIMENTAL
Intervention: Active exploration of a virtual forest (nature condition)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Slide show in VR (control condition)
Number of subjects: 22
Study: 18812128

Group type: EXPERIMENTAL
Intervention: Monarch III with D cartridge, direct implantation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Monarch III with D cartridge, wound-assisted implantation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Monarch II with C cartridge, direct implantation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Monarch II with C cartridge, wound-assisted implantation
Number of subjects: 100
Study: 16636364

Group type: EXPERIMENTAL
Intervention: Horsechestnut seed extract therapy combined with conventional therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 54
Study: 12792557

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 298

Group type: COMPARATOR
Intervention: No Acupuncture
Number of subjects: 298

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 298
Study: 10977025

Group type: EXPERIMENTAL
Intervention: Intensive treatment with insulin alone or with sulfonylurea (n = 75)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Standard once-daily insulin injection (n = 78)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Intensive treatment (n = 66)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Standard treatment (n = 70)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of 104 patients (STD, n = 53; INT, n = 51)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Abnormal LV ejection fraction at baseline
Number of subjects: 153
Study: 8841900

Group type: EXPERIMENTAL
Intervention: Systemic tetracycline (250 mg qds for 14 days)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Modified Widman flap surgery with adjunctive tetracycline
Number of subjects: 38

Group type: COMPARATOR
Intervention: Modified Widman flap surgery with placebo
Number of subjects: 38
Study: 1632100

Group type: EXPERIMENTAL
Intervention: Experimental gown
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard drape
Number of subjects: 87
Study: 29695594

Group type: EXPERIMENTAL
Intervention: Ofatumumab 3, 30, or 60 mg every 12 weeks, or 60 mg every 4 weeks
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Ofatumumab (all doses)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 26847290

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Optimal Medical Therapy (OMT)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 177
Study: 25004803

Group type: EXPERIMENTAL
Intervention: Interreality paradigm (Experimental Group, EG) for 5 weeks
Number of subjects: 121

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) (Control Group, CG) for 5 weeks
Number of subjects: 121
Study: 22872468

Group type: EXPERIMENTAL
Intervention: Oral peptone load (10 g)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Oral calcium load (1 g)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Oral peptone load with aluminum hydroxide (AH)
Number of subjects: 72
Study: 20688261

Group type: EXPERIMENTAL
Intervention: Music intervention (listening to chosen music for 30 minutes per week for 4 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 42
Study: 18096650

Group type: EXPERIMENTAL
Intervention: Movement training (PT-M group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Social training (PT-S group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Full-term infants (FT-S group)
Number of subjects: 39
Study: 16445598

Group type: EXPERIMENTAL
Intervention: Citrate buffer
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Histidine buffer
Number of subjects: 54
Study: 12913042

Group type: EXPERIMENTAL
Intervention: Questionnaire with opinion leaders' endorsement
Number of subjects: 395

Group type: COMPARATOR
Intervention: Questionnaire without endorsement (Control)
Number of subjects: 395
Study: 10997952

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (25 g CrH2O)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9075670

Group type: EXPERIMENTAL
Intervention: 1 mg terlipressin
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 2 mg terlipressin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 8368169

Group type: EXPERIMENTAL
Intervention: Inhalation of nebulized solution of non-bronchodilator (+) isoprenaline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10
Study: 3758469

Group type: EXPERIMENTAL
Intervention: HCT + AMI (50 mg/5 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: F + TRI (40 mg/50 mg)
Number of subjects: 10
Study: 29722590

Group type: EXPERIMENTAL
Intervention: Vitamin D3 capsule (5,000 IU/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 26684633

Group type: EXPERIMENTAL
Intervention: Intra-articular TNF blockers
Number of subjects: 82

Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 82
Study: 24857299

Group type: EXPERIMENTAL
Intervention: Tirofiban early treatment group (administered routinely at ≥ 4 hours prior to angiography)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (tirofiban provisional administered during or after angiography)
Number of subjects: 104
Study: 22672173

Group type: EXPERIMENTAL
Intervention: SMART card
Number of subjects: 125

Group type: COMPARATOR
Intervention: Northern Territory card
Number of subjects: 125

Group type: COMPARATOR
Intervention: Doctors
Number of subjects: 125

Group type: COMPARATOR
Intervention: All professional groups
Number of subjects: 125

Group type: COMPARATOR
Intervention: Sieve
Number of subjects: 125

Group type: COMPARATOR
Intervention: Sort
Number of subjects: 125
Study: 20059474

Group type: EXPERIMENTAL
Intervention: Systematic medication review and counselling by a clinical pharmacist and clinical pharmacologist
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual routine medication review in the ward
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Systematic medication review and counselling
Number of subjects: 100
Study: 18724193

Group type: EXPERIMENTAL
Intervention: Community Advisory Boards (CABs)
Number of subjects: 62
Study: 15809366

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/d)
Number of subjects: 9014

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study: 12182234

Group type: EXPERIMENTAL
Intervention: Mud pack treatment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Thermal bath treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy untreated subjects (control)
Number of subjects: 36
Study: 10726528

Group type: EXPERIMENTAL
Intervention: Surgical retreatment
Number of subjects: 95

Group type: COMPARATOR
Intervention: Nonsurgical retreatment
Number of subjects: 95
Study: 7579091

Group type: EXPERIMENTAL
Intervention: Loading dose of 400 mg and a daily dose of 200 mg/day for 9 days (Group 1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Loading dose of 200 mg and a maintenance dose of 100 mg/day for 9 days (Group 2)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Loading dose of 100 mg and a maintenance dose of 50 mg/day for 9 days (Group 3)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Loading dose of 200 mg and then 100 mg after each of four dialysis sessions (Group 4)
Number of subjects: 10
Study: 1954179

Group type: EXPERIMENTAL
Intervention: Initial chemotherapy followed by loco-regional treatment
Number of subjects: 272

Group type: COMPARATOR
Intervention: Initial chemotherapy
Number of subjects: 272
Study: 6800046

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin 800 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Azidocillin 750 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Antibiotics (Phenoxymethylpenicillin and Azidocillin)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin and Azidocillin
Number of subjects: 60
Study: 31663391

Group type: EXPERIMENTAL
Intervention: People with tinnitus (PwT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: People without tinnitus (PnT)
Number of subjects: 46
Study: 31135599

Group type: EXPERIMENTAL
Intervention: treadmill training and atDCS on Cz
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: treadmill training and atDCS on Cb
Number of subjects: 30

Group type: COMPARATOR
Intervention: treadmill training and sham tDCS on Cz
Number of subjects: 30
Study: 29289933

Group type: EXPERIMENTAL
Intervention: Antimicrobial central venous catheter (CVC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ordinary central venous catheter (CVC)
Number of subjects: 12
Study: 25635593

Group type: EXPERIMENTAL
Intervention: Norepinephrine 5 μg/ml
Number of subjects: 104

Group type: COMPARATOR
Intervention: Phenylephrine 100 μg/ml
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 104

Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Norepinephrine and Phenylephrine
Number of subjects: 104
Study: 23163915

Group type: EXPERIMENTAL
Intervention: DBBM-C/PG
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: β-TCP
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: DBBM-C/CM
Number of subjects: 40
Study: 21069355

Group type: EXPERIMENTAL
Intervention: Early feeding group (EFG) - oral liquid diet on the first postoperative day, advanced to regular diet within 24 hours as tolerated.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Traditional care group - nothing per orus until elimination of first flatus, then oral liquid diet followed by regular diet within 24 hours.
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Early feeding group (EFG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Traditional care group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study: 19060285

Group type: COMPARATOR
Intervention: SITA Standard
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GATE-i
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GATE
Number of subjects: 60

Group type: COMPARATOR
Intervention: Full-Threshold (FT)
Number of subjects: 60
Study: 17413628

Group type: COMPARATOR
Intervention: Local dry cold application
Number of subjects: 40

Group type: COMPARATOR
Intervention: EMLA cream application
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cold application and EMLA cream application
Number of subjects: 40
Study: 14592675

Group type: EXPERIMENTAL
Intervention: i.v. nicotine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: denicotinized cigarette smoke
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: i.v. nicotine and denicotinized smoke puffs
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: denicotinized smoke
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: i.v. nicotine and denicotinized smoke
Number of subjects: 18
Study: 10802893

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated estrogens and 2.5 mg medroxyprogesterone acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8820551

Group type: EXPERIMENTAL
Intervention: Judicially monitored mental health treatment
Number of subjects: 96

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 96
Study: 1483491

Group type: EXPERIMENTAL
Intervention: ANP‐270 0.3 micrograms/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ANP‐270 1.5 micrograms/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ANP‐270 3.0 micrograms/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2860162

Group type: EXPERIMENTAL
Intervention: Povidone-iodine lubricating gel (PVP-I)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (K-Y lubricating jelly)
Number of subjects: 30
Study: 29070503

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (60-70% peak oxygen uptake for 45 min, 3 days/week for 8 weeks)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 52
Study: 26317375

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Metabolic Activator Blend (MAB)
Number of subjects: 26
Study: 25008853

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (400 IU every other day)
Number of subjects: 14641

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (500 mg daily)
Number of subjects: 14641

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14641
Study: 22017475

Group type: EXPERIMENTAL
Intervention: Trans-apical LV lead implantation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Epicardial LV lead implantation
Number of subjects: 23
Study: 20467801

Group type: EXPERIMENTAL
Intervention: Assisted zona thinning (group 1A)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Not-thinned control (group 1B)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Assisted zona thinning (group 2A)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Not-thinned control (group 2B)
Number of subjects: 4
Study: 17700424

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) powder containing 60 million cells, twice daily for a minimum period of 7 days
Number of subjects: 235

Group type: COMPARATOR
Intervention: Oral rehydration solution (ORS) alone
Number of subjects: 235
Study: 16282839

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12131247

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (VO2peak)
Number of subjects: 30
Study: 10505821

Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 481

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 481
Study: 8951255

Group type: EXPERIMENTAL
Intervention: Prenatal pediatric visits
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 156
Study: 2254222

Group type: EXPERIMENTAL
Intervention: Clindamycin (300 mg qid for one day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no clindamycin)
Number of subjects: 8
Study: 7357803

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg every 8 hr for 1 wk
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Acebutolol 300 mg every 8 hr for 1 wk
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo every 8 hr for 1 wk
Number of subjects: 21
Study: 31785165

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 0
Study: 28115517

Group type: EXPERIMENTAL
Intervention: Renal denervation plus stepped-care antihypertensive treatment
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (stepped-care treatment alone)
Number of subjects: 97
Study: 26283629

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 50
Study: 24438478

Group type: EXPERIMENTAL
Intervention: Universal screening for GDM in primary care (n=392)
Number of subjects: 784

Group type: COMPARATOR
Intervention: Universal screening for GDM in secondary care (n=392)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Primary care screening
Number of subjects: 784

Group type: COMPARATOR
Intervention: Secondary care screening
Number of subjects: 784